You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALLO-605

Showing 1 - 25 of 436
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed/Refractory Multiple Myeloma Trial in United States (genetic, biological, drug)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • ALLO-605
  • +3 more
  • Denver, Colorado
  • +3 more
Feb 9, 2022

Diabetic Foot Ulcer Trial in Bucheon, Seoul (ALLO-ASC-DFU, Vehicle sheet)

Recruiting
  • Diabetic Foot Ulcer
  • ALLO-ASC-DFU
  • Vehicle sheet
  • Bucheon, Gyeonggi-do, Korea, Republic of
  • +3 more
Nov 15, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Germany (Cyclophosphamide (Non-IMP,

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • Cyclophosphamide (Non-IMP, Lymphodepletion)
  • +3 more
  • Ulm, Baden-Württemberg, Germany
  • +4 more
Jul 24, 2023

Leukemia, Lymphoid Trial in Chengdu (blinatumomab)

Recruiting
  • Leukemia, Lymphoid
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Oct 27, 2023

Transplantation, Hematopoietic Stem Cell Trial in Lyon (Biological samples (blood and oral fluid))

Not yet recruiting
  • Transplantation, Hematopoietic Stem Cell
  • Biological samples (blood and oral fluid)
  • Lyon, France
    Hôpital de la Croix Rousse - service des maladies infectieuses e
Jul 7, 2023

Alterations in Intestinal Microbiota, Metabolites, and Immune

Recruiting
  • Graft Vs Host Disease
  • Blood Sample
  • +2 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Nov 16, 2023

Myeloid Malignancies Trial in Chendu (fractionated busulfan-based conditioning regimen)

Recruiting
  • Myeloid Malignancies
  • fractionated busulfan-based conditioning regimen
  • Chendu, Sichuan, China
    West China Hospital, Sichuan University
Mar 29, 2023

Leukemia, Myeloid, Acute Trial in Chengdu (Chidamide)

Recruiting
  • Leukemia, Myeloid, Acute
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Dec 27, 2022

Prophylactic HQP1351 Therapy, Third Generation TKI Trial in Guanzhou (HQP1351( Olverembatinib dimesylate))

Withdrawn
  • Prophylactic HQP1351 Therapy
  • Third Generation TKI
  • HQP1351( Olverembatinib dimesylate)
  • Guanzhou, China
    Department of Hematology, Nanfang Hospital, Southern Medical Uni
Jan 16, 2023

CARPET Prognostic Model for Septic Shock After Allo-HSCT

Not yet recruiting
  • Stem Cell Transplant Complications
  • CARPET prognostic model
  • Beijing, Beijing, China
    Peking University Insititute of Hematology, Peking University Pe
Aug 31, 2023

AML, Adult, Minimal Residual Disease Trial in Guangzhou (chidamide and azacitidine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • chidamide and azacitidine
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Sep 27, 2023

Relapsed/Refractory Large B Cell Lymphoma Trial (biological, drug, genetic)

Not yet recruiting
  • Relapsed/Refractory Large B Cell Lymphoma
  • ALLO-647
  • +3 more
  • (no location specified)
Feb 6, 2023

Brain Neuronal Networks, Chemosensory and Trigeminal Functions

Recruiting
  • Hematopoietic Stem Cell Transplantation
    • Oslo, Norway
      University of Oslo
    Aug 21, 2023

    Bipolar Depression, MDD Trial in Chi?inau (Palmitoylethanolamide)

    Recruiting
    • Bipolar Depression
    • Major Depressive Disorder
    • Chișinău, Moldova, Republic of
      State University of Medicine and Pharmacy " Nicolae Testemitsanu
    Sep 26, 2023

    Acute Myeloid Leukemia Trial in Hefei (RC1012 injection (allo-DNT cells))

    Recruiting
    • Acute Myeloid Leukemia
    • RC1012 injection (allo-DNT cells)
    • Hefei, Anhui, China
      The First Hospital of the University of Science and Technology o
    May 17, 2023

    Poor Graft Function Trial (Decitabine, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonist)

    Not yet recruiting
    • Poor Graft Function
    • (no location specified)
    Jun 8, 2023

    Leukemia, Lymphoid Trial in Chengdu (blinatumomab)

    Not yet recruiting
    • Leukemia, Lymphoid
    • Chengdu, Sichuan, China
      West China Hospital of Sichuan University
    Oct 3, 2023

    Bronchiolitis Obliterans Syndrome, Hematologic Malignancy Trial in Hangzhou (Ruxolitinib)

    Recruiting
    • Bronchiolitis Obliterans Syndrome
    • Hematologic Malignancy
    • Hangzhou, Zhejiang, China
      The first Affiliated Hospital of Zhejiang University
    Oct 18, 2022

    Dose Optimization of Caspofungin in Adolescents

    Completed
    • Invasive Fungal Infections
    • Wuhan, China
      Wuhan Children's Hospital
    May 28, 2023

    Leukemia, Graft Failure Trial in Lille (eltrombopag)

    Recruiting
    • Leukemia
    • Graft Failure
    • Lille, France
      Hôpital Claude Huriez, CHU
    Aug 18, 2022

    Secondary Acute Myeloid Leukemia Evolving From MDS, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning Trial in

    Recruiting
    • Secondary Acute Myeloid Leukemia Evolving From MDS
    • +2 more
    • Granulocyte Colony-Stimulating Factor(G-CSF)
    • +4 more
    • Guangzhou, Guangdong, China
      Department of Hematology,Nanfang Hospital, Southern Medical Univ
    Jul 5, 2022

    Allo-HSCT as First-line Consolidation in High-risk PTCL

    Recruiting
    • T Cell Lymphoma
      • Beijing, China
        Peking University People's Hospital
      Jul 31, 2022

      Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning Trial in Guangzhou (Granulocyte

      Recruiting
      • Myelodysplastic Syndrome
      • +2 more
      • Granulocyte Colony-Stimulating Factor(G-CSF)
      • +5 more
      • Guangzhou, Guangdong, China
        Department of Hematology,Nanfang Hospital, Southern Medical Univ
      Jul 11, 2022

      CNS Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation Trial in Xi'an (TBF regimen, modified BuCY2 regimen)

      Not yet recruiting
      • Central Nervous System Leukemia
      • Allogeneic Hematopoietic Stem Cell Transplantation
      • TBF regimen
      • modified BuCY2 regimen
      • Xi'an, Shaanxi, China
        First Affiliated Hospital of Xi'an Jiaotong University
      Dec 26, 2022

      Hematologic Malignancy, Stem Cell Transplant Complications Trial in Beijing (Beijing protocol)

      Recruiting
      • Hematologic Malignancy
      • Stem Cell Transplant Complications
      • Beijing protocol
      • Beijing, Beijing, China
        Deparment of Hematology, Peking University People's Hospital
      Jun 19, 2023